Researchers have developed a blood test that can detect more than 50 common and deadly cancers, often before symptoms appear. The test could be especially useful in 12 cancers it was most accurate at detecting. These included pancreatic cancer, which is often only diagnosed at a very late stage and has poor outcomes and survival. […]
New test could spot early signs of prostate cancer
Posted: 3rd April 2020
Categories: Company news
Researchers have used genetic testing to detect the very early changes that occur in the tumours of men with prostate cancer. Researchers at the University College London (UCL) Cancer Institute say the new type of blood test will help them understand the genetic characteristics of the tumours that cause prostate cancer, which is the second […]
Yes. Onconomics and Onconomics Plus tests can be used for Ras-Raf-MEK-Erk, dabrafenib, vemurafenib, c-Jun, C-Fos, trametinib and sorafenib.
Can the Oncotrace test differentiate between benign and malignant tumour cells?
Yes. The Oncotrace test provides information about the presence of circulating tumour cells, their concentration and immunophenotype, which may help identify their origin. It is used to provide guidance about a patient’s prognosis, and to help identify the primary tumour when this is unknown.
I have a patient whose specific tumour appears to have resisting populations because of the overexpression of the MDR1 gene. This can be reversed by the use of inhibitors of ABG2 pumps. What do I do?
In this case, a patient could proceed with ketoconazole as a first-line treatment, and verapanib as a second-line treatment. Verapanib can contribute to a fall in blood pressure.
Didn't find an answer to your question? Contact us directly.